How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyclophosphamide-vindelsine-cytarabine-doxorubincin-prednisone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone (Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent, Topoisomerase inhibitor, Nucleoside analog, Anthracycline ant

phase 2 Alkylating agent, Topoisomerase inhibitor, Nucleoside analog, Anthracycline antibiotic, Corticosteroid DNA, Topoisomerase II, DNA polymerase, DNA, Glucocorticoid receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone (Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone) — Children's Cancer Group, China. Cyclophosphamide is an alkylating agent that interferes with DNA replication, Vindelsine is a topoisomerase inhibitor that disrupts DNA replication, Cytarabine is a nucleoside analog that inhibits DNA synthesis, Doxorubicin is an anthracycline antibiotic that intercalates DNA, Prednisone is a corticosteroid that suppresses inflammation and immune response.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone TARGET	Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone	Children's Cancer Group, China	phase 2	Alkylating agent, Topoisomerase inhibitor, Nucleoside analog, Anthracycline antibiotic, Corticosteroid	DNA, Topoisomerase II, DNA polymerase, DNA, Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agent, Topoisomerase inhibitor, Nucleoside analog, Anthracycline antibiotic, Corticosteroid class)

Children's Cancer Group, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclophosphamide-vindelsine-cytarabine-doxorubincin-prednisone. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab